Vanilloids in pancreatic cancer: potential for chemotherapy and pain management

Harte, M.; Di Mola, F. F.; Selvaggi, F.; Mascetta, G.; Wente, M. N.; Felix, K.; Giese, N. A.; Hinz, U.; Di Sebastiano, P.; Büchler, M. W.; Friess, H.
April 2006
Gut;Apr2006, Vol. 55 Issue 4, p519
Academic Journal
Background: Success of chemotherapy and alleviation of pain are frequently less than optimal in pancreatic cancer patients, leading to increasing interest in new pharmacological substances, such as vanilloids. Our study addressed the question of whether vanilloids influence pancreatic cancer cell growth, and if vanilloids could be used for pain treatment via the vanilloid 1 receptor (VR1) in pancreatic cancer patients. Methods: In vitro, the effect of resiniferatoxin (vanilloid analogue) on apoptosis and cell growth in pancreatic cancer cells—either alone, combined with 5-fluorouracil (5-FU), or combined with gemcitabine—was determined by annexin V staining, FACS analysis, and MTT assay, respectively. VR1 expression was evaluated on RNA and protein level by quantitative polymerase chain reaction and immunohistochemistry in human pancreatic cancer and chronic pancreatitis. Patient characteristics—especially pain levels—were registered in a prospective database and correlated with VR1 expression. Results: Resiniferatoxin induced apoptosis by targeting mitochondrial respiration and decreased cell growth in pancreatic cancer cells without showing synergistic effects with 5-FU or gemcitabine. Expression of VR1 was significantly upregulated in human pancreatic cancer and chronic pancreatitis. VR1 expression was related to the intensity of pain reported by cancer patients but not to the intensity of pain reported by patients with chronic pancreatitis. Conclusions: Resiniferatoxin induced apoptosis in pancreatic cancer cells indicates that vanilloids may be useful in the treatment of human pancreatic cancer. Furthermore, vanilloid might be a novel and effective treatment option for neurogenic pain in patients with pancreatic cancer.


Related Articles

  • Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. Zibing Wang; Yuqing Liu; Rui'e Li; Yiman Shang; Yong Zhang; Lingdi Zhao; Wei Li; Yonghao Yang; Xiaojie Zhang; Tiejun Yang; Changfu Nie; Feng Han; Ying Liu; Suxia Luo; Quanli Gao; Yongping Song // Journal of Hematology & Oncology;2/3/2016, Vol. 9, p1 

    Background: Advanced pancreatic cancer (PC) has very poor prognosis with present treatments, thus necessitating continued efforts to find improved therapeutic approaches. Both preclinical and preliminary clinical data indicate that cytokine-induced killer (CIK) cells are an effective tool...

  • miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Iwagami, Y; Eguchi, H; Nagano, H; Akita, H; Hama, N; Wada, H; Kawamoto, K; Kobayashi, S; Tomokuni, A; Tomimaru, Y; Mori, M; Doki, Y // British Journal of Cancer;7/23/2013, Vol. 109 Issue 2, p502 

    Background:Gemcitabine-based chemotherapy is the standard treatment for pancreatic cancer. However, the issue of resistance remains unresolved. The aim of this study was to identify microRNAs (miRNAs) that govern the resistance to gemcitabine in pancreatic cancer.Methods:miRNA microarray...

  • Stromal biology and therapy in pancreatic cancer: a changing paradigm. Neesse, Albrecht; Algül, Hana; Tuveson, David A.; Gress, Thomas M. // Gut;Sep2015, Vol. 64 Issue 9, p1476 

    Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid tumours and poses an unsolved problem in cancer medicine. Despite the recent success of two combination chemotherapies for palliative patients, the modest survival benefits are often traded against...

  • Failure as a route to success. CHANTRILL, LORRAINE // Australasian Science;Nov2015, Vol. 36 Issue 9, p33 

    The article focuses on the challenges that blocked the development of new treatments for pancreatic cancer. Topics include key characteristic of the cancer that impede the development of new treatments, the IMPaCT randomised clinical trial of genomically guided pancreatic cancer treatment, and...

  • P-0107 PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH ADVANCED PANCREATIC CANCER TREATED WITH GEMCITABINE: A RETROSPECTIVE ANALYSIS OF MULTICENTER STUDY. Ali, Inal; Tugba, Kos F.; Efnan, Algin; Ramazan, Yıldız; Veli, Berk; Tugba, Unek; Colak, Dılsen; Kaan, Helvacı; Caglayan, Geredeli; Faysal, Dane; Ozan, Balakan; Ayse, Durnalı; Hakan, Harputoglu; Suleyman, Buyukberber; Abdurrahman, Isıkdogan // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii46 

    No abstract available.

  • Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Kou, Tadayuki; Kanai, Masashi; Yamamoto, Michio; Xue, Peng; Mori, Yukiko; Kudo, Yasushi; Kurita, Akira; Uza, Norimitsu; Kodama, Yuzo; Asada, Masanori; Kawaguchi, Michiya; Masui, Toshihiko; Mizumoto, Masaki; Yazumi, Shujiro; Matsumoto, Shigemi; Takaori, Kyoichi; Morita, Satoshi; Muto, Manabu; Uemoto, Shinji; Chiba, Tsutomu // International Journal of Clinical Oncology;Feb2016, Vol. 21 Issue 1, p118 

    Background: We aimed to construct a prognostic model to predict survival in patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy using readily available pretreatment factors. Methods: The model was constructed using data from 306 consecutive patients with APC who...

  • A patient with unresectable advanced pancreatic cancer achieving long-term survival with Gemcitabine chemotherapy. Okamoto, Yoshiki; Maeba, Takashi; Kakinoki, Keitarou; Okano, Keiichi; Izuishi, Kunihiko; Wakabayashi, Hisao; Usuki, Hisashi; Suzuki, Yasuyuki; Bujanda, Luis // World Journal of Gastroenterology;11/28/2008, Vol. 14 Issue 44, p6876 

    A 68-year-old female visited a local clinic with epigastralgia. A routine laboratory test revealed jaundice and liver dysfunction. She was referred to this hospital. Abdominal computed tomography (CT) and endoscopic retrograde cholangio-pancreatography (ERCP) revealed that the density of the...

  • A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Roxburgh, Patricia; Lumsden, Graeme; Paul, James; Harden, Sharon; Sweeting, Lorna; James, Allan; Crellin, Adrian; Morrison, Rosemary; Evans, T.; McDonald, Alexander // Cancer Chemotherapy & Pharmacology;Jul2014, Vol. 74 Issue 1, p131 

    Purpose: The purpose of this phase I study was to determine the safety, toxicity, maximum tolerated dose, and pharmacokinetics of capecitabine when administered concurrently with radiotherapy in patients with localised, inoperable pancreatic adenocarcinoma. Methods: Eligible patients, with...

  • Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy. Sofuni, Atsushi; Itoi, Takao; Itokawa, Fumihide; Tsuchiya, Takayoshi; Kurihara, Toshio; Ishii, Kentaro; Tsuji, Syujiro; Ikeuchi, Nobuhito; Moriyasu, Fuminori; Karabacakoglu, Aydin // World Journal of Gastroenterology;12/21/2008, Vol. 14 Issue 47, p7183 

    AIM: To investigate if contrast-enhanced ultrasonography (CE-US) is useful for determining treatment efficacy and outcome in the early stages of pancreatic cancer chemotherapy by assessing changes in intratumor hemodynamics using CE-US with a contrast agent. METHODS: The subjects were 34...


Read the Article


Sign out of this library

Other Topics